22 Ces Urol 2022; 26(1): 13–28 PŘEHLEDOVÉ ČLÁNKY 2. Soares A, Maia MC, Vidigal F, Marques Monteiro FS. Cytoreductive Nephrectomy for Metasta‑ tic Renal Cell Carcinoma: How to Apply New Evidence in Clinical Practice. Oncology. 2020; 98(1): 1–9. doi:10.1159/000502778. 3. Howlader N, Noone AM, Krapcho M (eds). SEER Cancer Statistics Review (CSR) 1975-2018. [online]. Bethesda, MD [vid. 6. 1. 2022]. Dostupné z: https://seer.cancer.gov/csr/1975_2018/. 4. Middleton RG. Surgery for Metastatic Renal Cell Carcinoma. J Urol. 1967; 97(6): 973–977. doi:10.1016/ S0022-5347(17)63157-4. 5. Šámal V, Richter I, Paldus V, Jirásek T, Mečl J. Radiologická regrese metastatického renálního karcinomu po biologické léčbě sunitinibem - kazuistika a přehled literatury. Ces Urol. 2019; 23(4): 341–346. 6. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and Prognostic Stratifica‑ tion of 670 Patients With Advanced Renal Cell Carcinoma. J Clin Oncol. 1999; 17(8): 2530–2530. doi:10.1200/ JCO.1999. 17. 8.2530 7. Heng DYC, Xie W, Regan MM, et al. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study. J Clin Oncol. 2009; 27(34): 5794–5799. doi:10.1200/JCO.2008. 21. 4809. 8. Sobotka R, Tomáš H, Zemanová M. Zásadní význam chirurgické léčby u karcinomu ledvin, možnosti biologické léčby. Čas Lék čes. 2011; 150: 156–160. 9. Finke JH, Rayman PA, Ko JS, Bradley JM, Gendler SJ, Cohen PA. Modification of the Tumor Microenvi‑ ronment as a Novel Target of Renal Cell Carcinoma Therapeutics. Cancer J. 2013; 19(4): 353–364. doi:10.1097/ PPO.0b013e31829da0ae. 10. Lahn M, Fisch P, Kouml;hler G, et al. Pro‑Inflammatory and T Cell Inhibitory Cytokines Are Secreted at High Levels in Tumor Cell Cultures of Human Renal Cell Carcinoma. Eur Urol. 1999; 35(1): 70–80. doi:10.1159/000019821. 11. Bellardita L, Rancati T, Alvisi MF, et al. Predictors of health‑related quality of life and adjustment to prostate cancer during active surveillance. Eur Urol. 2013; 64(1): 30–36. doi:10.1016/j.eururo.2013. 01. 009. 12. Gatenby RA, Gawlinski ET, Tangen CM, Flanigan RC, Crawford ED. The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy. Cancer Res. 2002;62(18):5218-5222. 13. de Riese W, Goldenberg K, Allhoff E, et al. Metastatic renal cell carcinoma (RCC): Spontaneous regre‑ ssion, long‑term survival and late recurrence. Int Urol Nephrol. 1991; 23(1): 13–25. doi:10.1007/BF02549723. 14. Študentová H. Algoritmus léčby metastatického renálního karcinomu ledviny. Urol. praxi. 2011; 12(3): 152–157. 15. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy Followed by Interferon Alfa-2 b Compa‑ red with Interferon Alfa-2 b Alone for Metastatic Renal‑Cell Cancer. N Engl J Med. 2001; 345(23): 1655–1659. doi:10.1056/NEJMoa003013. 16. Mickisch G, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon‑alfa ‑based immunotherapy compared with interferon alfa alone in metastatic renal‑cell carcinoma: a rando‑ mised trial. Lancet. 2001; 358(9286): 966–970. doi:10.1016/S0140-6736(01)06103-7. 17. Larcher A, Wallis CJD, Bex A, et al. Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates? Eur Urol Oncol. 2019; 2(4): 365–378. doi:10.1016/j.euo.2019. 04. 007. 18. Méjean A, Ravaud A, Thezenas S, et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal‑Cell Carcinoma. N Engl J Med. 2018; 379(5): 417–427. doi:10.1056/NEJMoa1803675. 19. Bex A, Mulders P, Jewett M, et al. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib. JAMA Oncol. 2019; 5(2): 164. doi:10.1001/jamaoncol.2018.5543.
RkJQdWJsaXNoZXIy NDA4Mjc=